Perspectives on Stem Cell Therapy for Cardiac Regeneration

Choi, Sung Hyun; Jung, Sun Young; Kwon, Sang‐Mo; Baek, Sang Hong

doi:10.1253/circj.cj-11-1479

Cited by 49 publications

(30 citation statements)

References 83 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Total RNA was extracted using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) from mouse iPSC-derived EBs on days 6,8,12, and 19; cDNA was synthesized using the Super Script III First-strand Synthesis System (Invitrogen). PCR was performed with KOD-plus (Toyobo, Osaka, Japan).…”

Section: Reverse Transcription Polymerase Chain Reaction (Rt-pcr)mentioning

confidence: 99%

In Vivo Differentiation of Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Miyagawa

Miki

et al. 2013

Circ J

View full text Add to dashboard Cite

Section: Reverse Transcription Polymerase Chain Reaction (Rt-pcr)mentioning

confidence: 99%

In Vivo Differentiation of Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Miyagawa

Miki

et al. 2013

Circ J

View full text Add to dashboard Cite

“…As reviewed by Elnakish and colleagues, the use of MSCs in preclinical trials (especially in experimental animal models) showed an improvement of left ventricular function, a decreased size of infarcted area, and a decreased mortality [48]. Nevertheless, bone marrow (BM) and adipose tissue (AT) were extensively studied and still remain the major sources of adult stem cells used in most clinical trials, since their transplantation seems to be related to an improvement of heart physiology [49][50][51][52][53]. Coculture protocols with neonatal rat ventricular myocytes highlighted the cardiogenic potential of BM-MSCs, suggesting the influence of soluble factors [54].…”

Section: Bone Marrow and Adipose-derived Mes-enchymal Stem Cellsmentioning

confidence: 99%

New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells

Corrao¹,

Rocca²,

Iacono³

et al. 2013

CSCR

View full text Add to dashboard Cite

Cardiomyopathies are still the first cause of death in the world. The identification of resident stem cells, comprising those derived from sub-endocardial stroma, suggests the possible self regeneration of the heart under autocrine/paracrine modulation in the cardiac microenvironment. Nevertheless, because of the limited in vivo regeneration potential of damaged cardiac tissue, the use of drugs and ultimately cardiac transplantation remain the common treatments of heart diseases and defects. The differentiative potential of embryonic and mesenchymal stem cells (MSCs) derived from different tissues (such as bone marrow and adipose tissue) was extensively explored in cell therapy for regenerative medicine. Many groups have been focused, in recent years, on isolation, characterization, and differentiation potential of MSCs derived from perinatal (or extraembryonic) tissues, mainly the placenta and the human umbilical cord. In this review, we summarized recent works about the stemness of Wharton's jelly stromal cells and their potential in cardiac regeneration with favourable use in cell therapy and regenerative medicine. The peculiar features of these cells, as the expression of cardiac-specific transcription factors and immunomodulatory molecules suggest that human umbilical cord may be considered as a reliable alternative source of MSC useful for advanced therapy in cardiac regenerative medicine.

show abstract

“…Cardiomyocyte apoptosis is a major contributor to heart injury, morbidity and mortality. 4 We showed that cultured TKMSCs are more resistant to hypoxia-induced apoptosis compared to GFP-MSCs. It is possible that the higher tolerance of TK-MSCs to hypoxic conditions allowed these cells to engraft in the infarct area in greater number than GFP-MSCs.…”

Section: Discussionmentioning

confidence: 83%

“…Adult stem cells have been shown to provide cardiac protection, 1 and mesenchymal stem cells (MSCs) are a promising strategy for repairing and regenerating heart cells, and restoring heart function after an ischemic insult because of their ability to home to sites of tissue injury and inflammation. [2][3][4] In addition, MSCs exert paracrine actions that produce therapeutic effects, such as neovascularization and attenuation of cardiac remodeling. 2-4 Genetically modified MSCs have been shown to augment the protective effects of MSCs.…”

mentioning

confidence: 99%

Tissue Kallikrein-Modified Mesenchymal Stem Cells Provide Enhanced Protection Against Ischemic Cardiac Injury After Myocardial Infarction

Gao

Bledsoe

Yin

et al. 2013

Circ J

View full text Add to dashboard Cite

Background: Genetically modified mesenchymal stem cells (MSCs) are a promising approach to the treatment of cardiac injury after myocardial infarction (MI). Methods and Results:Rat MSCs were transduced with adenovirus containing human tissue kallikrein (TK) gene (TK-MSCs), and they secreted human TK into culture medium. Cultured TK-MSCs were more resistant to hypoxiainduced apoptosis and exhibited reduced caspase-3 activity compared to control GFP-MSCs. The effect of TK-MSC injection on cardiac injury was evaluated in rats at 1 and 14 days after MI. At 1 day after MI, human TK expression in the myocardium was associated with improved cardiac function and decreased inflammatory cell accumulation, proinflammatory gene expression and apoptosis. The beneficial effect of TK-MSCs against apoptosis was verified in cultured cardiomyocytes, as TK-MSC-conditioned medium suppressed hypoxia-induced apoptosis and caspase-3 activity, and increased Akt phosphorylation. At 2 weeks after MI, TK-MSCs improved cardiac function, decreased infarct size, attenuated cardiac remodeling, and promoted neovascularization, as compared to GFP-MSCs. Furthermore, the TK-MSC-conditioned medium, containing elevated vascular endothelial growth factor levels, stimulated the proliferation, migration and tube formation of cultured human endothelial cells. Conclusions:Our results indicate that TK-modified MSCs provide enhanced protection against cardiac injury, apoptosis and inflammation, and promote neovascularization after MI, leading to cardiac function improvement. (Circ J 2013; 77: 2134 -2144

show abstract

Perspectives on Stem Cell Therapy for Cardiac Regeneration

Cited by 49 publications

References 83 publications

In Vivo Differentiation of Induced Pluripotent Stem Cell-Derived Cardiomyocytes

In Vivo Differentiation of Induced Pluripotent Stem Cell-Derived Cardiomyocytes

New Frontiers in Regenerative Medicine in Cardiology: The Potential of Wharton’s Jelly Mesenchymal Stem Cells

Tissue Kallikrein-Modified Mesenchymal Stem Cells Provide Enhanced Protection Against Ischemic Cardiac Injury After Myocardial Infarction

Contact Info

Product

Resources

About